PROHANCE
Google image searchProduct monograph
Active ingredient
gadoteridol, 279.3 MG/ML
DIN: 02229056
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Schedule: Ethical
Company: BRACCO IMAGING CANADA
Date: 08-SEP-1998
ATC:
- V08 — CONTRAST MEDIA (ATC, ATC/DDD, )
- V08C — MAGNETIC RESONANCE IMAGING CONTRAST MEDIA (ATC, ATC/DDD)
- V08CA — Paramagnetic contrast media (ATC, ATC/DDD)
- V08CA04 — GADOTERIDOL (ATC/DDD)
Reference brand drug: Prohance
Pharmaceutical standard: USP
